The authors report 10 patients with idiopathic dermatomyositis treated with mycophenolate mofetil in combination with corticosteroids. Successful steroid taper without disease relapse was achieved in six patients; how...The authors report 10 patients with idiopathic dermatomyositis treated with mycophenolate mofetil in combination with corticosteroids. Successful steroid taper without disease relapse was achieved in six patients; however, in three patients, treatment was associated with opportunistic infections, leading to death in one patient. The disproportionately high rate of opportunistic infections in this group is considered.展开更多
The authors report a prospective pilot trial of etanercept in corticosteroid -dependent autoimmune myasthenia gravis. Eleven patients were enrolled, with e ight completing the 6-month trial. Two patients were withdraw...The authors report a prospective pilot trial of etanercept in corticosteroid -dependent autoimmune myasthenia gravis. Eleven patients were enrolled, with e ight completing the 6-month trial. Two patients were withdrawn owing to diseas e worsening, and one patient was withdrawn because of an erythematous skin rash. Six of the eight patients who completed the trial improved, based on quantitati ve measures of muscle strength and lowering of corticosteroid requirement.展开更多
文摘The authors report 10 patients with idiopathic dermatomyositis treated with mycophenolate mofetil in combination with corticosteroids. Successful steroid taper without disease relapse was achieved in six patients; however, in three patients, treatment was associated with opportunistic infections, leading to death in one patient. The disproportionately high rate of opportunistic infections in this group is considered.
文摘The authors report a prospective pilot trial of etanercept in corticosteroid -dependent autoimmune myasthenia gravis. Eleven patients were enrolled, with e ight completing the 6-month trial. Two patients were withdrawn owing to diseas e worsening, and one patient was withdrawn because of an erythematous skin rash. Six of the eight patients who completed the trial improved, based on quantitati ve measures of muscle strength and lowering of corticosteroid requirement.
